ArticleThrombosis research2022

Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE).

Parker Knueppel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.